Model for Predicting Serious Hematological Adverse Events in Individuals With Ovarian Cancer Receiving Poly (Adenosine Diphosphate Ribose) Polymerase Inhibitor Treatment: Prospective Cohort Study.

This study found that patients who experienced SHAEs showed a trend toward worse PFS than those without SHAEs (median 13.0, IQR 0.0-38.4 months vs median 24.0, IQR 19.2-28.8 months; P =.82); although no statistically significant difference was found, these toxicities still require early detection and proper management.

also in 53,322 other papers

In this study, although patients who developed hematological adverse events of a grade of ≥3 within the first month of PARPi treatment appeared to exhibit a higher DCR, this difference did not reach statistical significance.

also in 111,027 other papers